Ignite Creation Date:
2024-05-06 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 12:23 PM
Study NCT ID:
NCT03134066
Status:
COMPLETED
Last Update Posted:
2020-03-11
First Post:
2017-04-18
Brief Title:
Neurocognitive Features of Patients With Treatment-Resistant Depression
Sponsor:
Massachusetts General Hospital
Organization:
Massachusetts General Hospital
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2020-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
There is an urgent need for novel and effective interventions for treatment-resistant depression TRD In previous studies ketamine has been shown to rapidly reduce depressive symptoms however the exact mechanisms of action of ketamine remain unknown There are some preliminary findings to suggest that ketamine may exert its antidepressant effects through promotion of neurogenesis in the dentate gyrus The aim of this study is to help delineate the neurocognitive effects of ketamine exposure using a behavioral task specifically a pattern separation task and a battery of other well-established cognitive measures
This is an assessment-only study as we will be recruiting subjects to complete an assessment battery at two time points before and after receiving ongoing ketamine administrations for at least four weeks
This is an assessment-only study as we will be recruiting subjects to complete an assessment battery at two time points before and after receiving ongoing ketamine administrations for at least four weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None